Targeted therapy modalities
You will be able to: Separate what a therapy recognizes from how it acts and what evidence supports its use.
Two therapies can recognize the same protein and act differently. Two therapies can recruit T cells and recognize entirely different target types. Keeping recognition, drug format and clinical evidence separate makes comparisons much easier.
Before starting: HLA explains peptide presentation; the immunotherapy guide introduces the relevant cells and checkpoints.
The map
Target type, therapeutic format and clinical use are separate decisions.
Lessons
| Question | Lesson |
|---|---|
| What does each format do? | Mechanism |
| What determines readiness and duration? | Timing |
| What can be developed or given together? | Overlap and sequencing |
| How do I assess a proposal? | Decision questions |
| Which specimens support which experiments? | Tissue and sample budget |
| Which comparisons are easy to confuse? | Comparisons |
The big ideas
A target is not a dependency. A surface protein can help a drug enter a cell without being a growth driver. Its presence also does not show that an antibody can reach it or spare normal tissue.
HLA (human leukocyte antigen) independence is specific to recognition. A surface-target CAR (chimeric antigen receptor) or antibody engager can recognize its target without peptide display on HLA. A TCR (T-cell receptor)-based engager still requires its particular peptide–HLA target. Neither format automatically overcomes poor T-cell function, failed trafficking or suppression in the tumor.
Availability is specific to the product and setting. An approved therapy for one cancer does not establish an approved use in early TNBC. A laboratory binder is an experimental reagent until format-specific engineering, manufacture, safety testing and a clinical pathway are established. One binder cannot be assumed to work unchanged in every format.
Local ablation has a different starting point: it destroys tissue without molecular target recognition. Its proposed systemic immune effects are a separate hypothesis, covered in local-treatment modalities.
Try it
A proposal says, “This therapy recruits any T cell, so HLA loss cannot affect it.” What is missing?
Explain it back: The target-recognition arm. A surface-protein engager can be independent of HLA for recognition; a peptide–HLA engager cannot. Effective killing also depends on T-cell function, access and target expression.
Explain it back
Name the target, recognition system, format, intended clinical setting and supporting evidence before comparing therapies.
Takeaway
Name the target, recognition system, format, intended clinical setting and supporting evidence before comparing therapies.
Applied to Diana
Treatment status belongs in the care plan, unresolved choices in questions, and provider-specific capabilities in companies. A mechanism lesson does not establish eligibility or a treatment plan.
Vocabulary: ADC means antibody-drug conjugate.
Sources
Checked October 8, 2026.
- NCI: targeted therapy.
- FDA: tebentafusp mechanism review — a TCR–CD3 engager recognizing gp100 peptide on HLA-A*02:01.
- NCI: T-cell transfer therapy.
Concepts you will use
HLA and clinical actionability.
What is still uncertain
Clinical benefit and combination safety require evidence for the actual product, population and setting. Mechanism alone cannot resolve those questions.